ES2361566T3 - Uso de inhibidores de parp-1. - Google Patents

Uso de inhibidores de parp-1. Download PDF

Info

Publication number
ES2361566T3
ES2361566T3 ES06840026T ES06840026T ES2361566T3 ES 2361566 T3 ES2361566 T3 ES 2361566T3 ES 06840026 T ES06840026 T ES 06840026T ES 06840026 T ES06840026 T ES 06840026T ES 2361566 T3 ES2361566 T3 ES 2361566T3
Authority
ES
Spain
Prior art keywords
parp
inhibitor
composition
amount
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06840026T
Other languages
English (en)
Spanish (es)
Inventor
Kathleen A. Scotto
Michael Mandola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of ES2361566T3 publication Critical patent/ES2361566T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06840026T 2005-11-25 2006-11-27 Uso de inhibidores de parp-1. Active ES2361566T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73953605P 2005-11-25 2005-11-25
US739536P 2005-11-25

Publications (1)

Publication Number Publication Date
ES2361566T3 true ES2361566T3 (es) 2011-06-20

Family

ID=38068066

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06840026T Active ES2361566T3 (es) 2005-11-25 2006-11-27 Uso de inhibidores de parp-1.

Country Status (9)

Country Link
US (1) US20090170860A1 (enExample)
EP (1) EP1962843B1 (enExample)
JP (1) JP2009517403A (enExample)
AT (1) ATE499098T1 (enExample)
AU (1) AU2006318226A1 (enExample)
CA (1) CA2630900A1 (enExample)
DE (1) DE602006020335D1 (enExample)
ES (1) ES2361566T3 (enExample)
WO (1) WO2007062413A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
EP2207548B1 (en) * 2007-10-09 2013-05-22 Malka Cohen-Armon Breast cancer therapy
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
EP2870140B8 (en) 2012-07-09 2016-09-28 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
SG11201503670YA (en) 2012-12-31 2015-07-30 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN108368059B (zh) * 2016-04-18 2022-02-01 深圳市塔吉瑞生物医药有限公司 一种取代的酞嗪酮化合物及其药物组合物
KR20180097876A (ko) * 2017-02-24 2018-09-03 주식회사 온코크로스 1,5-이소퀴놀린디올을 포함하는 피부 노화 방지 및 주름 개선용 조성물
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
JP4824566B2 (ja) * 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Ｐａｒｐを阻害するための化合物、方法、および医薬組成物
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US20050187172A1 (en) * 2003-12-23 2005-08-25 Masferrer Jaime L. Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)

Also Published As

Publication number Publication date
EP1962843A2 (en) 2008-09-03
EP1962843A4 (en) 2009-08-12
US20090170860A1 (en) 2009-07-02
WO2007062413A3 (en) 2007-12-27
JP2009517403A (ja) 2009-04-30
ATE499098T1 (de) 2011-03-15
DE602006020335D1 (de) 2011-04-07
WO2007062413A2 (en) 2007-05-31
CA2630900A1 (en) 2007-05-31
AU2006318226A1 (en) 2007-05-31
EP1962843B1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
ES2361566T3 (es) Uso de inhibidores de parp-1.
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
US20200206188A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US11491154B2 (en) Therapeutic benefit of suboptimally administered chemical compounds
JP6280546B2 (ja) ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
US20240285632A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
CN111053768A (zh) 用于治疗黑素瘤的药物组合
US20130079401A1 (en) Novel use of isothiocyanates for treating cancer
US20210283109A1 (en) Heterocyclic diamidines
JP2003525255A (ja) ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
CN101808636A (zh) 黑色素瘤的治疗
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
AU2017214157A1 (en) Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis
EP1771174A1 (en) Method for treating abnormal cell growth
CN101171013A (zh) 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
ES2363394B2 (es) Uso de amitriptilina como agente antitumoral para el tratamiento de cáncer de pulmón.
Greco Synthesis and biological evaluation of pyrazolo [3, 4-d] pyrimidine derivatives active as SGK1, Fyn and Src kinases inhibitors
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma